March 3, 2021 -- Merck has received about $269 million in U.S. funding to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 vaccines and medicines.
The Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, will provide Merck with $268.8 million to adapt and make available multiple existing manufacturing facilities to produce SARS-CoV-2/COVID-19 vaccines and medicines.
Also, Merck signed a deal with Janssen Pharmaceuticals. Merck will support the manufacturing and supply of the Janssen COVID-19 vaccine. Merck will use its facilities in the U.S. to produce drug substance, formulate, and fill vials of Janssen's vaccine.